Read more about the article Gastric and GEJ cancers – Keytruda to HER2+ patients, improves outcomes
סרטן קיבה, ושט-קיבה – קיטרודה לחולי הר2+ משפרת יעילות

Gastric and GEJ cancers – Keytruda to HER2+ patients, improves outcomes

Background The first findings of KEYNOTE-811, an ongoing, global phase III trial, found that the addition of Keytruda to Herceptin plus chemotherapy for first-line treatment in patients with HER2-positive unresectable…

Continue ReadingGastric and GEJ cancers – Keytruda to HER2+ patients, improves outcomes